HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on UroGen Pharma, maintaining a price target of $60.
October 15, 2024 | 9:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on UroGen Pharma, maintaining a price target of $60, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $60 price target by HC Wainwright & Co. suggests a positive outlook for UroGen Pharma. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100